ARTICLE | Clinical News
MOR00208: Phase II started
April 18, 2016 7:00 AM UTC
MorphoSys began the open-label, international Phase II L-MIND trial to evaluate 12 mg/kg IV MOR208 plus once-daily oral Revlimid lenalidomide in 4-week cycles in 80 patients who previously received 1...